There are hundreds of point solutions claiming AI in oncology. Very few of them survive contact with a real clinical workflow, a real payer, or a real regulatory review.
We evaluate AI in oncology the way we evaluate everything else: independently, and against what it actually costs to run.
AI Stalls for Predictable Reasons
Clinician resistance. Workflow disruption. Unclear return. The technology is rarely the failure point. The failure point is deploying it into an operating model that was never adjusted to receive it.
The vetting problem is real too. Vendors compete on algorithmic claims, which is the least useful basis for a decision. What determines whether a tool works is workflow fit, data requirements, output interpretability, implementation cost, vendor lifecycle risk, and who is liable when it is wrong.
What We Do
Independent Software Vetting
Competing options assessed on workflow fit, data requirements, output interpretability, implementation cost, and vendor viability, with a clear recommendation and an implementation roadmap.
Cost Analysis and Value Realization
Software, hardware, staffing, and training modeled against throughput, denial reduction, and documentation impact, tied to measurable outcomes.
Legal and Regulatory Review
Liability, scope of practice, reimbursement risk, and alignment with CMS, FDA, and payer frameworks, assessed before deployment.
No Vendor Relationships, No Endorsement Money
Our recommendation is the one we would make if we were paying for it. Bridge holds no equipment affiliations and takes no endorsement money, which in a market this crowded is the difference between an evaluation and a referral.
We also design the adoption pathway, not just the decision. That means aligning stakeholders, embedding the technology inside the actual clinical workflow, and measuring outcomes against the business case that justified it.
And we are in this conversation publicly. Bridge publishes and speaks on where AI in oncology is heading, which is how we bring future-state thinking to a decision you have to make this quarter.
A complimentary AI strategy consult gives you an independent read on where the technology fits your program and what it will actually cost to run.
